Also known as: Erythropoietin-derived peptide
A peptide based on EPO that protects nerves without raising red blood cells.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Activates the innate repair receptor (EPO receptor plus CD131), calming inflammation and supporting small-nerve regrowth.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Nerve pain & neuropathy | B | Human trials (smaller, mixed, or approved outside the US) |
| Blood sugar & metabolic | C | Limited human data, case series or practitioner reports |
At a glance
- Route
- Subcutaneous daily
- Half-life
- Minutes; effects last weeks
Reported dosing
4 mg SC daily for 28 days (trial dose).
Timing: Once daily.
Cycle: 28-day course.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Injection-site reactions
- Generally well tolerated
Who should avoid it
- Pregnancy
Often combined with
Alone.
Key findings
Phase 2 trials in sarcoidosis and type 2 diabetes improved small-fiber nerve density and neuropathic pain.
Where it is legal (Oct 2026)
| US | Not approved |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open ARA-290 (Cibinetide) in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.